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E rosette formation by peripheral blood T lymphocytes 
was studied during photochemotherapy (PUV A) of pso-
riasis. Prior to PUV A treatment the percentage of E 
rosette forming cells was found to be markedly de-
creased in patients with active psoriasis, whereas it was 
normal ill those with inactive skin lesions. 
In the initial phase of PUV A therapy (within the first 
2 weeks) single PUV A exposure induced the decrease of 
the percentage of E rosettes in patients with psoriasis, 
but not in normal controls. This immediate suppression 
of E rosette formation, which persisted for more than 24 
hr, was related to combined 8 MOP + UV A action, but 
not to 8 MOP or UV A irradiation alone. T lymphocytes 
reacquired an initial number of E rosette forming cells 
48 hr after the last PUV A exposure. 
PUV A-induced inhibition of E rosette formation was 
most prominent in patients with inactive psoriasis in 
whom the initial percentage of E rosettes before treat-
ment was normal. A lesser degree of decrease of E rosette 
forming cells after PUV A exposure was observed in 
patients with active psoriasis and reduced initial per-
centage of E rosettes_ 
The suppression of E rosette formation caused by 
PUV A exposure was related to the presence of psoriatic 
lesions, since it could not be demonstrated after clearing 
of skin changes. 
Irrespective of preceding activity of the disease, E 
rosette formation showed a gradual improvement with 
PUV A therapy. The reduction in the percentage of E 
rosettes completely disappeared in the fourth week of 
PUV A treatment, which was correlated with healing of 
skin lesions. Almost all patients with psoriasis (85%) 
recovered normal E rosette function up to 1 mo after 
termination of PUV A treatment. 
Patients with psoriasis have been found to have abnormalities 
in cell-mediated immune response. The frequency and intensity 
of experimentally induced hypersensitivity to DNCB was sig-
nificantly lower in the patients than in normal population 
[1,2]. Decrease in lymphocyte response to nonspecific mitogens 
(PHA [phytohemagglutinin], Con A [concanavalin A], and 
PWM [pokeweed mitogen]) was also reported by several au-
thors [3-5]. 
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These abnormalities were not related to the reduction of T 
cell count. Decreased E rosette formation in patients with 
psoriasis, previously described by Cormane et al [6] Guilhou et 
al [4], and Glinski et al [7] was found to be dependent on 
defective function of T lymphocytes [8]. Furthermore, the 
reduction in E rosettes and decreased DNCB sensitization in 
psoriasis was related to the activity of the disease, but not to 
the extension of skin lesions [1,7]. The supression of E rosette 
formation could be restored by in vitro short-term preincuba-
tion of psoriatic lymphocytes with Con A, and disappeared 
during remission of the disease [8]. 
Finally, the sera of patients with psoriasis were found to 
contain a factor inhibiting normal T lymphocyte E rosette 
function, the concentration of which increased within 2 mo of 
recent relapse of skin lesions [8l 
The percentage of E rosette forming cells were also studied 
in patients with psoriasis receiving PUVA therapy. Cormane et 
al [9,10] have observed decrease in the number of rosetting 
lymphocytes in the patients and normal controls after 4 PUV A 
exposmes. The percentage of E rosettes returned to the starting 
range after 8 PUVA exposures, but was still significantly lower 
in psoriatics than in normals. 
A marked reduction in E rosettes and normal number ofEAC 
rosettes in PUVA-treated patients were reported by Ortonne et 
al [11]. The initial percentage of E rosette forming cells in those 
patients was found to be normal. Unfortunately, there were no 
data concerning clinical state of patients with psoriasis, the 
number and frequency of PUV A exposures, and the time rela-
tion of the E rosette test to the last PUV A irradiation. 
The purpose of our paper was to determine a short-term 
effect of individual PUV A exposure as well as a long-term effect 
of PUV A therapy on peripheral blood lymphocytes forming E 
rosettes in patients with psoriasis with varying activity and 
extent of skin lesions. 
MATERIALS AND METHODS 
S election of Patients 
58 patients with psoriasis vulgaris receiving PUV A photochemo-
therapy were studied. Control group consisted of 5 patients treated 
with PUV A for other purposes (2 urticaria pigmentosa, 2 vitiligo and 1 
pre-mycosis fungoides), and 26 normal volunteers. Two clinical criteria 
were used for classification of patients with psoriasis: 1. activity of the 
disease, and 2. extent of skin lesions. The activity of cutaneous lesions 
was defined as: A2-pin-point lesions, small, papules spreading, positive 
Kobner phenomenon; Al-active spreading peripheraUy plaque lesions 
with only occasionally small papules; and AO-skin lesions stationary 
for a long period of time (more than 3 mol. The extent of skin changes 
was also graded in terms of surface occupied by psoriatic lesions: Bl-
less than 10%, B2-10-40%, and B3-more than 40%. 
Patients with psoriasis had never received PUV A photochemother-
apy, and corticosteroids or immunosuppressive drugs systemically be-
fore they were included into the study. Prior to PUV A therapy the 
patients had been only treated externally with tars, corticosteroid 
ointments, anthralin and salycilic acid. 
To obtain comparable results individuals who were extremely sen-
sitive to sunlight have not been included into our experiments. 
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P U V A Treatment 
8- methoxypsoralen (8 MOP) (Methoxalen, Westwood Pharm. Inc. ) 
was administered ora lly in doses of 0.8-0.9 mg/ kg body weigh t 2 hI' 
be fo re UV A irradiation. 
U VA ligh t source was a 4-well stand-up cabinet containing 112 60 
cm-long fluorescent lamps in a horizontal plane. This source emits a 
con t inuous spectrum of irradiation between 320-400 nm wavelength 
w it h peak emission at 365 nm. The energy delivered was on average 
2.7- 3 .5 mw/cm" at a distance of 10 em from the flu orescent la mps. 
The patients were irradiated in an alte rnate day schedule (excluding 
S unday) 3 t imes a week. The dose of UV A used fo r the first 3 P UV A 
exp osures varied from 2.4 to 2.7 J /cm", and starting from the 4th UV A 
irradiation a dose was increased to 3.2-3.6 J / cm". Number of PU VA 
exp osures necessary for cl earing of psoriatic lesions varied from 12 to 
25 (average 15.1) in this group of pa tients. T otal UV A dose received by 
indiv idua l patient was about 35-78 J /cm" (mean 49 J / cm"). 
T iming of Sep arate Exp eriments 
T hree different schedules of blood drawing fo r the determination of 
E r osette forming cells were used: A. for each patient: l. before the 
PUV A therapy; 2. after every 3 PUV A irradiations (once a week) on a 
d ay of in termission between 2 consecut ive PUV A exposures (3rd and 
4th, 6th and 9th, 9th and lOth, etc. ; and 3. 1 mo a fter complet ion of 
PUVA therapy. 
B . A t differen t times of P UVA treatmen t (P UVA exposure [1-18]) 
twice da ily: just before oral administration of 8MOP and 2 hl' before 
UV A irradiation, and 1 hr after PUV A exposure. 
C. Between two consecut ive PUVA exposures (N o. 3- 4, 4-5, or 5-6): 
2 h I' before PU V A exposure, 1 hr a fter P UV A irradiation, 24 hI' a fte r 
PUV A exposure, and 48 hr afte r P UV A exposure (just before admin-
istration of 8 MOP prior to the next PUVA irradiation) . 
E Rosette T est 
Peripheral blood lymphocytes were isolated on a Ficoll-Ronpacon 
gradient of specific gravity 1.078 by a method described by Boyum 
[ 12 ]. S ponta neous rosette forma t ion wi th sheep erythrocytes (SHBC) 
by lymphocytes was studied by a modification of the method ofW ybra n 
et a l (13). 
B riefly, S RBC were washed 3 times in Ha nks' medium and cent ri-
fu ged at 400 xg for 5 min . 0.2 ml of lymphocyte suspension (4 X 10'/ 
mI) was added to 0.2 011 of 0.5% v/ v washed SRBC, a nd 0.2 ml heat-
in activated SRBC-absorbed fetal calf serum. Lymphocyte:el'ythrocyte 
ratio was 1:10. The mixture was incubated for 45 min at 37°C, centri -
fuged at 200 xg fo r 5 min, and kept overnight at 4°C. 
Lymphocytes surrounded by 3 or more erythrocytes were considered 
as E rosettes. The percentage of lymphocytes forming E rosettes wi th 
SRB C was calculated for 400 consecut ive lymphocytes. 
T ests were done in duplicate for each patient and mean results 
accepted if the percentage of E rosettes in both samples differed by not 
m o re than 5%. 
RESULTS 
Once a W eek Determination of E R osette Formation During 
P UVA Treatment 
A . in relation to activity of the disease. Prior to PUVA 
t r eatment the percentage of E rosette formin g cells was found 
to be decreased in 70% of patients with psoriasis (23 out of 33) 
compared to normal controls. Most of these cases were distrib-
uted into both groups of patients with active skin lesions (A2 
a nd AI). The initia tion of PUVA thera py induced the subse-
quent reduction of starting value of E rosettes in 42% of cases 
(14 out of 33). This was shown almost exclusively in patients 
with inactive skin lesions (AO) who were found to have normal 
initial distribution of E rosette forming cells (62.3%) before 
o n set of PUV A therapy. 
In active psoriasis (group Al and A2) the percentage of E 
rosette forming cells increased gradually between every 3 
PUV A i.rradiations reaching the normal value of rosetting cells 
after 9 or 12 PUVA exposures respectively (Fig 1). P atients 
w ith inactive psoriasis (group AO) showed a marked reduction 
in E rosettes after 3 PUVA exposures (47.7%), which persisted 
aft er 6 PUVA (51.6%), but returned to normal range after 9 
PUVA exposures (60.1%). 
In t he majority of patients t he increase in the percentage of 
E rosette forming cells was correlated with t he flattening and 
disappearing of psoriatic lesions. 
There was no decrease of t he percentage of E rosettes within 
the first 2 weeks of PUV A treatment in control groups consisted 
of 3 normals and the 5 patients receiving photochemoth erapy 
for other purposes. 
B . in relation to the extension of shin. lesion.s. Examination 
after every 3 P U V A exposures showed no significa nt difference 
in the percentage of E rosette forming cells between groups of 
patients with varying extent of skin involvement (B I, B2, and 
B 3) (Fig 2). An ini t ial mean percentage of E rosettes prior to 
PU V A therapy, and that after 3 PUV A as well as 6 PUV A 
exposures were markedly decreased. In all t hese clinical groups 
E rosette formation after 9, 12, and 15 PUV A irradiations was 
found to be normal. The reduction of ini t ial percentage of E 
rosettes after I week of P UV A therapy (3 P UV A exposures) 
was relatively greater in group Bl and B3 than in group B2. 
However , most of patients with inactive psoriasis was distrib-
uted in to these 2 groups. 
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E Rosette Formation 1 Month after Completion of PUVA 
Treatment 
PUV A therapy was effective in all our patients, whose pso-
riatic lesions cleared within 4-8 weeks and did not relapse for 
more than 1 mo despite of discontinuation of the treatment. 
Irrespectively of initial activity and extent of psoriatic lesions 
prior to PUV A 85% of patients (28 out of 33) free of skin lesions 
reacquired normal E rosette formation up to 1 mo after termi-
nation of PUV A therapy in contrast to only 30% of cases 
showing normal number of E rosettes before PUV A treatment 
(Table I). The remaining 5 patients were found to have only a 
slight decrease in E rosettes compared to normal controls, but 
the percentage ofrosetting cells in these cases was much greater 
than that before starting of PUVA therapy. There was no 
difference between the mean percentage of E rosette forming 
cells in patients with psoriasis symptom-free for 1 mo after 
PUV A treatment and healthy normals. 
Suppression of E Rosette Formation with Single PUVA 
Exposure 
In patients with inactive psoriasis a reduction of the percent-
age of E rosette forming cells (47.2%) appeared as early as 1 hr 
after termination of individual PUV A exposure as compared to 
64.1 % of E rosettes before PUV A irradiation (Table Il). The 
suppression of E rosette formation was still present after 24 hr 
(52.0%), whereas after 48 hr just before the subsequent PUV A 
exposure .patients reacquired normal E rosette function (66.8%). 
Only a slight decrease of percentage of E rosette forming cells 
from 67.8% before PUV A exposure to 61.2% 1 Ill" after PUV A 
exposure was found in healthy normals. The difference between 
these 2 mean numbers of E rosettes was not statistically sig-
nificant. 
The decrease in the percentage of E rosettes was found in 
patients with psoriasis receiving 8 MOP followed by irradiation 
with UVA light (46.4%), but not treated with 8 MOP alone 
(65.8%) or UVA alone (61.5%) (Table III). Repeated UVA 
inadiations alone did not induce the reduction of the number 
Vol. 72, No.5 
of rosetting cells 24 hr after 3 PUVA exposures (62.1%) in 
contrast to combined 8 MOP + UVA treatment (49.4%). 
Effect of Single PUVA Exposure on Psoriatic Lymphocytes 
at Different Times of Photochemotherapy 
The comparison of E rosette test before and 1 hr after PUV A 
exposure revealed that the percentage of E rosette forming cells 
was significantly reduced, up to 32% of lymphocytes, in 20 out 
of 29 patients with psoriasis studied at different times of PUV A 
therapy (Table IV). The marked decrease of about one third of 
lymphocytes forming E rosettes (45.7%) within initial phase of 
therapy (1-5 PUVA exposures) was found in all patients, who 
previously had the normal percentage of E rosette forming cells 
(67.1%). In patients with active psoriasis with reduced initial 
percentage of E rosette forming cells (42.0%) only about 15% of 
lymphocytes were inhibited in their E rosette function by single 
PUV A exposure (35.7%). This was demonstrated in 5 of 9 these 
patients 1 hr after PUV A exposure in the first 2 weeks of PUV A 
treatment. 
After further irradiations (7-18 PUVA exposures) 5 of 10 
cases who showed a marked decrease in E rosettes were found 
to have persistent elevated psoriatic lesions. No reduction in E 
rosettes was observed in those almost free of skin lesions. 
DISCUSSION 
The present data implies that at least 2 distinct phenomena 
involving T lymphocyte subpopulaticns compete with each 
other during PUV A treatment of psoriasis, immediate suppres-
sion of T cells after PUV A and a gradual improvement in the 
T cell function with therapy. 
Individual PUVA exposure immediately induced the sup-
pression of T lymphocyte E rosette formation in patients with 
psoriasis, but not in normal controls. This lasted for more than 
24 hr after inadiation, whereas before subsequent PUVA ex-
posme 48 hr later T lymphocytes reacquired theil' normal 
function. These fmdings are in agreement with communications 
of Cormane et al [9,10] and Ortonne et al [11] who reported on 
TABLE I. E rosette forming cells in 33 patients with p soriasis before and after P UVA photochemotherapy 
% E Roselte forming lymphocytes 
Clinical No. of pa· 
slate lienls Before PUV A lreatmenl % patienls wilh I mo afler PUV A treatment 
Mean SO Range decrease
fl 
Mean SO Range 
Tota l 33 52.5" 16.5 30.5-82.5 70 64.7 15.1 31.5-80 
Activity 
AO 11 59.8" 7.8 47-70 36 62.3 13.0 31.5-74 
A1 13 51.6" 13.6 30.5-82.5 77 66.3 8.9 50-79 
A2 9 44.8" 7.4 31-55 100 65.4 8.5 53-80 
Extention 
Bl 8 57.3" 8.4 47-70 62 63.9 7.1 50-74 .5 
B2 14 47.4" 10.2 30.5-64 85 67.3 8.6 52.5-80 
B3 11 55.5" 11.0 30.5-68 55 62.0 12.8 31.5-73 
Normal 20 68.5 5.7 58.5-80.5 
" More tha n 2 SD be'low the mean percentage of E rosette forming cells in normal controls. 
"." S ignificantly different from normals/t-tes t, " = p < ' 0.001, ,. = p < 0.002. 
% patients wilh Slatistica l difference 
decrease" (I. test) 
15 P < 0.005 
18 NS 
15 P < 0.005 
11 P < 0.001 
37 NS 
7 P < 0.001 
9 NS 
TABLE II. E rosette formation after individual PUVA exposure in 7 patients with inactive psoriasis during photochemotherapy (3rd-5th 
PUVA exposure) and 7 normal controls (lst-2nd PUVA exposure) 
% E rosette forming cells 
Time of examina- Psoriasis (7) Normal (7) Statistical difference from con· tion trol (I-test) 
Mean SO Range Mean SO Range 
1. B efore PUV A 64.1 4.9 57-70 67.8 6.2 59-77.5 NS 
After PUVA 
2. 1 hI' 47.2" 7.5 36-55 61.2 7.8 53.5-74 P < 0.01 
3. 24 hr 52.0" 6.5 44-61 69.6 6.4 58-79 p < 0.001 
4.48 hI' 66.8 4.8 62-76 66.5 6.8 57.5-76 NS 
"." significa ntly different from group 1 (t-test) ; " = p < 0.002, and " = p < 0.01. 
May 1979 T LYMPHOCYTES ANO PUVA TREATMENT IN PSORIASIS 217 
TABLE Ill. The percentage of E rosette forming cells after oral admin.istration of 8 MOP alone, UVA irra.diation alone, and combined 
application of 8 MOP + UVA in patients with p soriasis 
Inactive psoriasis 
1. 8 MOP (6) 
2. UVA (4) 
3. 8 MOP + UVA (S) 
" 3 hr after 8 MOP. 
b 1 hI' after UV A. 
Before 
mean ± SO 
62.2 ± 7.8 
66.0 ± 6.S 
60.6 ± 6.3 
% E rosette form ing cells 
1 hI' after 1st applicai ion 
mean ± SO 
6S.8 ± 6.7" 
61.S ± 3.8" 
46.4 ± 8.4"''' ' 
24 hI' after 3rd applica tion 
mean ± SO 
62.1 ± 4.3 
49.4 ± 8.0" 
c Group 3 significantly different from group 1 (p < 0.005), and group 2 (p < O.OS) (t-test). 
TABLE IV . Immediate effect of individual PUVA exposure on peripheral blood lymphocytes of 29 patients with psoriasis at different p eriods 
of PUVA therapy 
% E rosette fo rming cells 
Group No. of PUVA Before PUV A exposure 1 hI' after PUVA exposure Patients with de· Absolute % reduc- t· test exposure crease" tion of E rosettes 
Mean SO Range Mean SO Range 
Ina c tive psoriasis (10) 1-5 67.1 8.8 57-87 45.7 8.5 30-55 10/ 10 - 12 - -32 p < 0.001 
Active psoriasis (9) 1-5 42.0 6.8 35-56 35.7 8.4 20.5-48 5/ 9 +2 - - 14.5 NS 
Further phase of PUV A, dis-
ease activity undefined" 
7-18 58.8 13.8 31.5-71.5 56.7 14.4 22-70 5/ 10 +14--15 NS 
(10) 
Total (29) 1-18 56.5 14.4 31.S-87 46.4 13.6 20.5- 70 20/ 29 +14 - - 32 P < 0.02 
" M ore than 5% of lymphocytes below an initial percentage of E rosettes before PUV A irradiation. 
" Actual activity of skin lesions impossible to assess precisely with regard to clinical improvement-before t reatment mostly active lesions. 
the depression in E rosette number in patients receiving PUVA 
therapy. The inhibitory effect of PUVA exposure on peripheral 
blood lymphocytes of psoriatic patients was due to combined 8 
MOP and UV A action. 8 MOP alone and UV A light alone had 
no influence on the relative number of rosetting cells. 
Since immediate suppression of E rosette formation with 
PUV A exposure occurred usually in the initial phase of the 
treatment (within the first 2 weeks) 01' after further irradiations 
only in patients whose skin lesions were relatively resistant, it 
seemed to be related to the presence of psoriatic lesions of both 
active and inactive type. 
In active psoriasis in respect of diminished initial number of 
E rosettes an additional reduction of the percentage induced by 
PUV A was relatively small. In contrast, the immediate sup-
pression was found to be responsible in patients with inactive 
psoriasis for extreme reduction of rosetting T cells within initial 
phase of PUV A therapy from norma! level prior to the treat-
ment to the range comparable to that of patients with active 
lesions. 
The gradual improvement ofE rosette format ion with PUVA 
therapy was found in patients with both active and inactive 
psoriatic lesions in whom lymphocyte subpopulations were 
followed up once a week on a day after every 3 PUV A exposures. 
At this time the immediate suppression of T cells caused by 
preceding PUV A exposure, if present, should be still demon-
strated because it lasts for more than 24 hI'. T lymphocyte 
rosetting function became normal in the third week of PUV A 
tratment which was correlated to flattening of skin lesions. 
Further irradiations (12-15 PUV A exposures) did not induce 
t he immediate suppression of E rosette formation in patients 
with clinical improvement or in those almost free of skin lesions. 
T lymphocyte quantitation in this phase of PUV A and 1 mo 
after completion of the treatment remained normal in almost 
all cases irrespectively of initial disease activity and extent of 
psoriatic lesions. This is in agreement with our previous data 
on the restoration of T cell function in the remission of psoriasis 
[7,8). 
The mecha nism of reduction in the percentage of T lympho-
cytes forming E rosettes dUJ'ing PUVA treatment is not clear. 
In vitro irradiation of peripheral blood lymphocytes with PUVA 
was found to inhibit lymphocyte transformation to nonspecific 
rnitogens [14] , and spontaneous incorporation of tritiated thy-
midine [15]. However, it is not clear if this effect could be due 
to either inhibition of DNA synthesis by 8 MOP-DNA pho-
toadduct formation, or incr eased cell death in the phototoxic 
reaction. 
The immediate inhibitory effect of PUV A exposure on T cells 
could be related to: 1. the irradiat ion of recirculating lympho-
cytes in cutaneous infiltrates and capillaries with a PUVA dose 
adequate to inhibit T lymphocyte function (direct mechanism), 
and/ or (2) the release of inhibiting factors (i.e., immune com-
plexes) from skin lesions into the circulation (indirect mecha-
nism). 
Close relation of the PUV A-induced depression of E rosette 
formation to th e presence of skin lesions may argue for both an 
indirect mechanism of T cell inhibition and direct suppression 
of the function of recirculating lymphocytes. It is quite clear 
that indirect inhibition related to released factors should dis-
appear with clearing of psoriatic lesions. Similarly, the absence 
of diJ'ect immediate suppression of T cells in intermediate phase 
of PUV A treatment might be explained by th e disappearance 
of lymphocyte inftitration [16) and reduced blood flow through 
skin capillaries in healing cutaneous lesions [17) as well as an 
adequate protection against PUVA by hyperpigmented skin. 
It should be stressed that PUV A appeared to be unable to 
suppress E rosette formation of more than one half of T 
lymphocytes in patients with psoriasis. This could be also 
explained by direct or indirect mechanism of PUV A action. Not 
all lymphocytes recirculating through the skin could receive 
UV A dose adequate to inhibit their rosetting function. How-
ever, in active psoriasis in contrast to inactive psoriasis the 
number of T cells which are sensitive to PUV A il'l'adiation is 
relatively low despite of similar distribution of skin lesions. In 
active psoriasis T lymphocytes might be all'eady inhibited with 
underlying unknown factors (perhaps previously described 
blocking factors in psoriatic sera [8). The defect of E rosette 
formation in these patients could be unblocked in vitro by 
preincubation of lymphocytes with Con A [8). 
PUV A exposure may provoke the release of inhibiting factors 
from skin lesions, which subsequently inhibit E rosette forma-
tion, but only of T cell subpopulation exhibiting affinity to 
those factors. In inactive psoriasis T lymphocytes sensitive to 
the action of blocking factors might be previously unaffected, 
so the greater number of T cells than in active psoriasis could 
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be suppressed after release of inhibiting factors stimulated by 
PUV A irradiation. 
The alternative mechanism of PUV A-induced inhibition of 
T cell function remains to be elucidated. 
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Corrected Date for the 
International Symposium 
on the Treatment of 
Psoriasis and Psoriatic Arthritis 
This international symposium had been previously scheduled for February 1979 and will now be held 
from November 18-25, 1979. Speakers include Drs. T . J . Ryan. F. Sagher. N. Hjorth. and H. Maibach. 
The offici.allanguage of the Symposium is English. The sessions will take place in Tel Aviv and the Dead 
Sea. Information can be obtained by writing or cabling N. D. Yahalom, 44 Ibn Gvirol. Tel Aviv, Israel. 
The meeting is sponsored by the Dermatology Department of the Hadassah Hospital. The Israeli 
Dermatologic Society. and the International Psoriasis Treatment Center. 
